Silence Therapeutics plc
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $400.00K | $-0.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $159.00K | $-0.15 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $224.00K | $-0.19 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $142.00K | $-0.20 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | – | – | – |
Press releases
Announcements Silence Therapeutics filed with the SEC
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Material agreement · Other events · EX-99.1 to Form 8-K
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
August 10, 2026 SANRECO Phase 2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
June 2026 Corporate Presentation EXHIBIT 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
March 2026 Corporate Presentation Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Silence Therapeutics Announces Leadership Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Other events · EX-99.1 to Form 8-K
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera
EX-99.1 to Form 6-K
Condensed consolidated income statement (unaudited)
EX-99.1 to Form 6-K
Condensed consolidated income statement (unaudited)
EX-99.1 to Form 6-K
Polycythemia Vera June 27, 2024
EX-99.2 to Form 6-K
Silence Therapeutics Announces Positive Topline 48-Week Data from
EX-99.1 to Form 6-K
Condensed consolidated income statement (unaudited)
EX-99.1 to Form 6-K
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
EX-99.1 to Form 6-K
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
EX-99.1 to Form 6-K
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
EX-99.3 to Form 6-K
Condensed consolidated income statement (unaudited)
EX-99.1 to Form 6-K
Condensed consolidated income statement (unaudited)
EX-99.1 to Form 6-K